Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

▤ Summary

Nuvectis expanded its pipeline by licensing ex-China rights to two clinical-stage compounds from Haisco Pharmaceutical Group. The deal adds NXP100, a late-stage oral complement Factor B inhibitor, and NXP200, a paradox-breaker BRAF inhibitor for oncology. Nuvectis says the move shifts it into a late-stage clinical development profile and supports future growth in complement-mediated disease and cancer. The transaction includes upfront and milestone payments, and Nuvectis still needs to satisfy financing conditions to fully support development. The company also highlighted ongoing China regulatory and clinical progress for both assets and outlined the commercial potential of the two markets.

▦ Linked Companies